Filing Details

Accession Number:
0000950170-24-003076
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-01-08 18:01:26
Reporting Period:
2024-01-05
Accepted Time:
2024-01-08 18:01:26
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1937653 Zymeworks Inc. ZYME Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1938192 Andrew Paul Moore C/O Zymeworks Inc.
108 Patriot Drive, Suite A
Middletown DE 19709
Chief Scientific Officer No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2024-01-05 17,166 $0.00 17,166 No 4 M Direct
Common Stock Disposition 2024-01-05 7,460 $10.65 9,706 No 4 S Direct
Common Stock Disposition 2024-01-08 2,339 $11.22 7,367 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Restricted Stock Unit Disposition 2024-01-05 17,166 $0.00 17,166 $0.00
Common Stock Stock Option (Right to Buy) Acquisiton 2024-01-05 90,000 $0.00 90,000 $10.56
Common Stock Restricted Stock Unit Acquisiton 2024-01-05 60,000 $0.00 60,000 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
34,334 No 4 M Direct
90,000 2034-01-04 No 4 A Direct
60,000 No 4 A Direct
Footnotes
  1. Represents shares of common stock issued upon vesting of one third of the restricted stock units ("RSUs") granted on January 5, 2023.
  2. Represents shares of common stock sold to cover tax withholding obligations and other applicable fees in connection with the vesting of RSUs pursuant to mandatory "sell to cover" provisions contained in the Reporting Person's applicable RSU grant agreement, and does not represent a discretionary sale by the Reporting Person. The Reporting Person did not sell or otherwise dispose of any of the shares reported on this Form 4 for any reason other than to cover required taxes and fees.
  3. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $10.55 to $10.845, inclusive. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
  4. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $10.49 to $11.58, inclusive. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
  5. Each RSU represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock.
  6. The RSUS were granted on January 5, 2023 and vest in three equal annual installments beginning on January 5, 2024.
  7. Stock options vest as follows: (i) 25% of underlying shares of common stock on first anniversary of grant date and (ii) remainder of underlying shares of common stock in 36 equal monthly installments on last day of month following first anniversary of grant date.
  8. The RSUs vest in three equal annual installments beginning on January 5, 2025.